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Kinetics in Signal Transduction Pathways
Involving Promiscuous Oligomerizing
Receptors Can Be Determined by Receptor
Specificity: Apoptosis Induction by TRAIL*□S
Eva Szegezdi,a,b Almer M. van der Sloot,b,c,d Devalingam Mahalingam,a Lynda O’Leary,a
Robbert H. Cool,e Ine´s G. Mun˜oz,g Guillermo Montoya,g Wim J. Quax,e Steven de Jong,f
Afshin Samali,a,h and Luis Serranoc,i,j
Here we show by computer modeling that kinetics and
outcome of signal transduction in case of hetero-oli-
gomerizing receptors of a promiscuous ligand largely de-
pend on the relative amounts of its receptors. Promiscu-
ous ligands can trigger the formation of nonproductive
receptor complexes, which slows down the formation of
active receptor complexes and thus can block signal
transduction. Our model predicts that increasing the re-
ceptor specificity of the ligand without changing its bind-
ing parameters should result in faster receptor activation
and enhanced signaling. We experimentally validated this
hypothesis using the cytokine tumor necrosis factor-re-
lated apoptosis-inducing ligand (TRAIL) and its four
membrane-bound receptors as an example. Bypassing
ligand-induced receptor hetero-oligomerization by recep-
tor-selective TRAIL variants enhanced the kinetics of re-
ceptor activation and augmented apoptosis. Our results
suggest that control of signaling pathways by promiscu-
ous ligands could result in apparent slow biological kinet-
ics and blocking signal transmission. By modulating the
relative amount of the different receptors for the ligand,
signaling processes like apoptosis can be accelerated or
decelerated and even inhibited. It also implies that more
effective treatments using protein therapeutics could be
achieved simply by altering specificity Molecular & Cellu-
lar Proteomics 11: 10.1074/mcp.M111.013730, 1–13, 2012.
To enable diverse biological responses, many ligand-recep-
tor systems consist of multiple receptors and/or ligands (1–4).
Predicting the biological response in such a multicomponent
system can be complex: the presence of the receptors and
ligands does not guarantee that the signal is transmitted. The
response can be dictated by the final equilibrium distribution
of the ligand with the different receptors, but it is equally
possible that the biological effect is more dynamically driven
by temporal kinetic effects of the ligand interacting with its
receptors (5). This may be the case in particular when the
ligand has a short half-life time. In fact, there is evidence that
kinetics could play an important role in the outcome of a
signal (6). In a simple network, an interaction with similar Kd
but having different kon and koff values could respond differ-
ently with a short or a long pulse of a ligand. In these multi-
component systems, mathematical modeling is an invaluable
tool to understand and predict the outcome of the signaling
events (6).
In principle, excluding well known effects like macromo-
lecular crowding or protein immobilization, one could as-
sume that it should be possible to extrapolate kinetic and
equilibrium constants from in vitro to in vivo conditions,
provided that the in vitro conditions reflect the in vivo ones.
However, this simple assumption could fail if the molecule
that triggers a signal can be trapped in nonproductive in-
teractions that equilibrate slowly with the productive com-
plex. This can significantly slow down or even block the
progression of a signal. In such cases, one could imagine
that increasing the specificity of the ligand toward the pro-
ductive complex could result in faster kinetics of receptor
activation (7). Moreover, if this is the case, it could affect the
way many signal transduction pathways are analyzed and
simulated because it is conceivable that this scenario could
be very common.
To explore this possibility, we have selected a relatively well
understood signal transduction pathway that involves both a
promiscuous ligand and nonproductive - (receptor-ligand)
complex formation, the TNF-related apoptosis-inducing li-
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gand (TRAIL)-induced1 apoptotic pathway (8). TRAIL is in-
volved in tumor immune surveillance and is an attractive
candidate as an anti-cancer therapeutic because it induces
apoptosis in a wide range of tumor cells, but not in nontrans-
formed cells (9). TRAIL has five receptors: death receptor-4
(DR4, TRAIL-R1), death receptor-5 (DR5, TRAIL-R2), decoy
receptor-1 (DcR1, TRAIL-R3), decoy receptor-2 (DcR2,
TRAIL-R4), and a secreted receptor, osteoprotegerin. TRAIL
induces apoptotic cell death via binding to DR4 or DR5 (10).
Upon binding TRAIL, the receptors recruit the adaptor mole-
cule Fas-associated death domain (FADD) to their cytoplas-
mic death domains. Pro-caspase-8, the apical enzyme of the
apoptosis-inducing proteolytic enzyme cascade, then binds
to FADD, dimerizes and becomes active. Active caspase-8
induces apoptosis by activating downstream members of the
protease cascade, such as caspase-3, -6, and -7 (type I
apoptosis) (11), or by cleaving and activating a pro-apoptotic,
Bcl-2 protein family member, Bid, which triggers cytochrome
c release from the mitochondria, thus amplifying the apoptotic
trigger by activating the intrinsic pathway of apoptosis (type II
apoptosis) (12). It is broadly accepted that lower levels of
caspase-8 trigger apoptosis through the type II pathway (10,
13). In numerous tumors, however, the intrinsic pathway of
apoptosis is blocked by overexpression of anti-apoptotic
Bcl-2 proteins or the caspase-9 and -3 inhibitor, XIAP (X-
linked apoptosis inhibitor protein). Consequently, if the level of
pro-caspase-8 activation fails to reach a certain threshold, the
short half-life of active caspase-8 (20 min) in combination
with the various anti-apoptotic molecules present in the cell
will block the progression of the apoptotic signal, and the
cell will not commit to death (14, 15). Thus, a timely and
efficient pro-caspase-8 activation is a key factor in TRAIL-
induced apoptosis (15–17).
Binding of TRAIL to its other three receptors does not
induce apoptosis (18). Osteoprotegerin is a secreted, soluble
receptor and has a negative regulatory role in TRAIL signaling
by sequestering TRAIL from DR4 and DR5. In contrast, DcR1
and DcR2 are membrane-bound and transmembrane recep-
tors, respectively. Neither DcR1 nor DcR2 can recruit FADD
upon TRAIL binding; therefore they are believed to act as
decoy receptors (18), and overexpression of DcR1 or DcR2
has been shown to inhibit TRAIL-induced apoptosis (19–21).
The mechanism by which DcR1 and DcR2 block TRAIL-in-
duced apoptosis is thought to involve not only sequestration
of TRAIL from DR4 and DR5 but also by formation of inactive,
heteromeric complexes with DR4 or DR5 upon exposure to
TRAIL (ligand-dependent hetero-oligomerization) (20). Decoy
receptors have also been suggested to hetero-oligomerize
with DR4 and DR5 in a ligand-independent fashion through
their preligand assembly domains (PLAD) present on the N-
terminus of the receptors (22–25). It is unclear, however, what
the individual contributions of the various mechanisms in this
process are. Given the fact that TRAIL has a much lower
affinity for its decoy receptors than for DR5 (26), a sequestra-
tion-only mechanism in which decoy receptors simply act as
a TRAIL sink will not work when similar amounts of receptor
are present. Likewise, with the ligand-dependent or ligand-
independent DcR2/DR4/5 hetero-oligomerization, the equilib-
rium distribution between the receptors will not be changed
much because of these affinity differences and hence cannot
be responsible for observed antagonistic effects either.
Using biochemical data from the literature and this study,
we have modeled the activation of the TRAIL receptors upon
binding TRAIL using SmartCell (27). Our simulations suggest
that the receptor toward which the ligand has the highest
specificity—but without necessarily having increased kinetic
binding constants—will be activated much faster than the
other receptors and will therefore be the main determinant of
the signal transduction pathway activated. To verify whether
this prediction holds in cells, we have used a TRAIL variant
that selectively binds to DR5 (D269H/E195R) (28). This TRAIL
variant has proved to be a very potent inducer of apoptosis in
tumor cell lines where the DR5 receptor is active both in vitro
(28) and in vivo (29). Using this TRAIL variant as a tool, we
found that receptor-specific TRAIL variants exhibit much
faster receptor activation kinetics, confirming the prediction of
the model. We also show that this multireceptor system works
in concert to create a temporal control of apoptosis induction
and, under physiological conditions, can act as a safeguard
against unwarranted induction of apoptosis. Thus, our results
indicate that kinetics of signal transduction induced by pro-
miscuous ligands are largely determined by nonproductive
interactions and, consequently, by the relative amount of the
different receptors sharing the same ligand.
MATERIALS AND METHODS
Cell Culture and Treatments—Colo205 cells were cultured in RPMI
1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 50
units/ml penicillin, 5 mg/ml streptomycin, and 10 mM sodium pyru-
vate. The cells were treated with recombinant human TRAIL
(nontagged, amino acids 114–281 fragment), Wt TRAIL, or DR5-
specific TRAIL variant, D269H/E195R, which were produced and
purified as described before (28, 30). Analytical gel filtration and
nonreducing gel electrophoresis confirmed that D269H/E195R is a
trimeric molecule that does not form higher degree aggregates (28).
Soluble DR5 receptor, DcR1 and DcR2, and neutralizing antibodies to
DcR1 and DcR2 were all from R & D Systems. Other reagents were
from Sigma-Aldrich unless otherwise stated.
MTT Assay—Cell viability was measured by adding 500 g/ml MTT
to control and treated cells and incubated for 3 h at 37 °C. The
reaction was stopped, the purple formazan precipitate formed was
dissolved in 10% dimethyl formamide and 20% sodium dodecyl
sulfate, and the color intensity was measured at 550 nm using a
1 The abbreviations used are: TRAIL, tumor necrosis factor-related
apoptosis-inducing ligand; DR, death receptor; DcR, decoy receptor;
FADD, Fas-associated death domain; PLAD, preligand assembly do-
main(s); MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide; DEVD, carbobenzoxy-Asp-Glu-Val-Asp-7; AMC, amino-4-
methylcoumarin; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-
1-propanesulfonic acid; XIAP, X-linked inhibitor of apoptosis protein;
WT, wild type; CARP, caspase-8 and -10 associated RING protein.
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Wallac multilabel counter (32). The control value corresponding to
untreated cells was taken as 100%, and the viability of treated sam-
ples was expressed as a percentage of the control.
Annexin V Staining—Externalization of phosphatidylserine on the
plasma membrane of apoptotic cells was detected using annexin
V-FITC (IQ Corporation, Groningen, The Netherlands) and flow cy-
tometry (FACSCanto II flow cytometer; Becton Dickinson) as previ-
ously described (33).
Western Blotting—Polyacrylamide gel electrophoresis and West-
ern blotting was carried out as previously described (34). For antigen
detection, membranes were incubated with antibodies to actin (1:500;
Sigma), caspase-3 and -8 (1:1,000; Cell Signaling Technologies) over-
night at 4 °C followed by 2 h of incubation at room temperature with
appropriate secondary antibodies (1:5,000; Pierce). Protein bands
were visualized using Supersignal Ultra Chemiluminescent Substrate
(Pierce) on x-ray film (Agfa).
Detection of Caspase Activity—Cells (3  105) were resuspended
in PBS (25 l) and were transferred to a microtiter plate and snap-
frozen over liquid nitrogen. To initiate the reaction, 50 M of the
caspase substrate DEVD-AMC (Peptide Institute Inc., Osaka, Japan)
in assay buffer (100 mM Hepes buffer, 10% sucrose, 0.1% CHAPS, 5
mM DTT, and 0.0001% Igepal 630, pH 7.25) was added to cell lysates.
Substrate cleavage leading to the release of free AMC was monitored
at 37 °C at 60 s intervals for 25 cycles using a Wallac multilabel
counter (excitation, 355 nm; emission, 460 nm). Enzyme activity was
expressed as nmol of AMC released/min/mg protein.
SPR Receptor Binding Assay—Binding experiments were per-
formed as previously described (28).
Cell Surface Expression of TRAIL Receptors—The cells were
washed twice in PBS containing 1% BSA and then incubated with
monoclonal antibodies to DR4, DR5, DcR1, or DcR2 (Enzo Life Sci-
ences) for 40 min. The antibodies have no cross-reactivity among the
four TRAIL receptors (shown by the Supplier’s data sheet). After two
wash steps with PBS/BSA, anti-mouse IgG-FITC (Sigma) secondary
antibody was added for 30 min. All of the incubations were carried out
on ice. Negative controls contained isotype control antibody. Recep-
tor expression was analyzed on a FACSCalibur or FACSCanto II flow
cytometer (Becton Dickinson).
Mathematical Modeling of Ligand Receptor Interaction—Receptor
binding by WT TRAIL and D269H/E195R on the cell surface was
simulated using a mathematical model describing all of the possible
binding events. Both the formation of homotrimeric (e.g. TRAIL-3DR5)
and heterotrimeric ligand receptor complexes (e.g. TRAIL-2DR5-
DcR2) were allowed, and binding was simulated in a stepwise fashion
(Fig. 1). On-rates and off-rates measured for interactions between
monomeric DR4, DR5, DcR1 and DcR2 receptors and of TRAIL
binding to these receptors were taken from the report of Lee et al.
(25), where monomeric TRAIL receptor constructs have been em-
ployed. This allowed us to derive stepwise binding constants and to
model heteromeric receptor-ligand interactions (Fig. 1 and sup-
plemental Table 2). Stepwise constants for going from a single ligand-
bound receptor, via two ligand-bound receptors, to the complex
consisting of three receptors bound by a trimeric ligand were esti-
mated in the following way: the kon reported by Lee et al. was
assigned to the first binding event. The first association step is en-
tropically the most unfavorable one because of the loss of rotational
degrees of freedom when going from an unbound state to a bound
state. To compensate for this entropic penalty in the first step, the Kd
for the second and third step was decreased by 2 kcal/mol and
attributed completely to an increase in kon (35, 36). The values of 0 to
4 kcal/mol for the entropy penalty were tested; the impact on the
final results was negligible. The reported koff was assigned to the first
step. Two scenarios were explored: 1) no cooperative binding, i.e.
binding of one receptor does not enhance the binding of the next
receptor (supplemental Table 2) and 2) cooperative binding, whereby
binding to the first receptor enhances the binding of a second recep-
tor of the same type (supplemental Table 2). Cooperativity can be the
result of interaction between the intracellular death domains of the
DR4 or DR5 receptors, as has been shown for FAS, another death
receptor (37). Thus, to model cooperativity, the koff was decreased
stepwise 5-fold in each subsequent binding reaction (38, 39). Varying
this factor between 2 and 10 revealed little impact on the final results.
In case of homotrimeric TRAIL-3DR5 and TRAIL-3DR4 complexes, an
extra step to an “activated” receptor complex was introduced to
mathematically describe the assembly of the intracellular death-in-
ducing signaling complex (consisting of the death receptors, FADD,
and caspase-8). As mentioned before, DcR1 does not contain an
intracellular domain, and DcR2 only contains a truncated Death do-
main; therefore no “activation” step was added for decoy receptor
containing complexes (supplemental Table 2). The rate constants for
the “activation” step that governs the formation of activated homotri-
meric death receptor complexes were obtained by increasing the kon
and decreasing the koff by a factor of ten relative to the rate constants
of the third step (supplemental Table 2). The presence of an activation
step was necessary for scenario 1 (no cooperative effects upon
binding additional receptor units) to drive TRAIL-3DR4/TRAIL-3DR5
complex formation, but the effect of the actual magnitude of this step
was low upon varying this factor between 2 and 10 (relative to the rate
constants of the third step). The impact on inclusion of an activation
step for scenario 2, the cooperative model, was relatively low.
Reaction equations describing the binding of TRAIL to preas-
sembled dimeric receptor complexes was modeled in the following
way: the kon of the first step (kon
A) and the koff of the second step (koff
B)
were attributed to binding equations describing free TRAIL binding a
preassembled receptor complex, and in case of equations describing
the binding of single bound TRAIL (i.e. TRAIL-DR5) to a preassembled
receptor complex, the kon of the second step (kon
B) and the koff of the
third step (koff
C) were attributed to the reaction. When the preas-
sembled receptor complex was a heterodimer (i.e. DR5-DR4), the rate
constants of the receptor with the rate-limiting kinetics, i.e. the re-
ceptor having the slowest kon and the fastest koff, were chosen.
The number of DR5 receptors on the surface of Colo205 was
estimated by comparing the receptor expression level on the surface
of Colo205 to MDA-MB-231 cells and subsequently relating this ratio
to the number of surface expressed receptors determined for MD
MBA-231 cells (40) (supplemental Fig 1 and Table I). The relative
expression of the four TRAIL receptors at the single cell level has also
been estimated by simultaneously labeling all four receptors using
four separate fluorochromes for the four anti-TRAIL receptor antibod-
ies and analysis of the fluorescence intensity on 10,000 cells by flow
cytometry. By selecting the cells expressing very similar levels of one
receptor, the expression of the other three receptors on the same
subset of cells was analyzed. Apparent affinities for D269H/E195R
were taken from van der Sloot et al. (28). The increase in affinity of
D269H/E195R for DR5 was completely attributed to the kon and was
determined to be 3–5-fold, because changes in the off rate in the SPR
sensorgram between WT TRAIL and D269H/E195R could not be
calculated because of a minimal and very slow rate of ligand disso-
ciation. The decrease in affinity of D269H/E195R for the other recep-
tors was equally attributed to the kon and the koff based on previous
studies (28). The rate constants for the equation describing the for-
mation of the activated death receptor complexes were derived as
described above for WT TRAIL.
To mimic the local concentration of the receptors at the cell mem-
brane, a volume equal to sphere of 10 nm around a typical mamma-
lian cell was taken as the simulation volume (13.9 m3). The initial
steady state distribution of the receptors between monomeric, ho-
modimeric and heterodimeric species was obtained by running the
Specificity of Promiscuous Ligands Regulates Signaling Kinetics
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model with the TRAIL concentration set at 0. Unless otherwise spec-
ified, all of the simulations were performed at a TRAIL concentration
of 25 ng/ml (1.3  109 M). The model was simulated using the
stochastic next subvolume method (41, 42) as implemented in Smart-
Cell version 4.3 (27, 43). SmartCell is available at http://
software.crg.es/smartcell.
RESULTS
Mathematical Modeling of Ligand Receptor Interaction—To
investigate the hypothesis that the kinetics of receptor acti-
vation of promiscuous ligand receptor systems is governed by
nonproductive heteromeric interactions and that the kinetics
of such systems could be modified by changing specificity,
we simulated the TRAIL ligand receptor interaction occurring
on the cell surface using a mathematical model. The model
was set up to simulate the interactions occurring on the
membrane of Colo205 cells upon exposure of the cells to WT
TRAIL or the DR5-selective variant D269H/E195R (28) (Fig. 1).
TRAIL mediates cell death in Colo205 cells by directly acti-
vating the downstream caspase members of the protease
cascade (type I apoptosis) (11) and does not require activation
of the intrinsic apoptotic pathway (supplemental Fig. 2).
The ratio of DR4, DR5, DcR1, and DcR2 was set to reflect
the true ratio of the four receptors on the surface of Colo205
cells as described under “Materials and Methods” (sup-
plemental Fig. 1 and Table I), and the ratio of TRAIL receptor
expression has been estimated at single cell level by simul-
taneous fluorescent (multicolor) labeling the four TRAIL recep-
tors (supplemental Fig. 1C). Subpopulations of cells that ex-
pressed very similar amount of one receptor showed a much
wider distribution for the expression of the other three recep-
tors. Nonetheless, there was a proportional relationship in
TRAIL receptor expression; higher expression of one receptor
correlated with a higher average expression of the other three
receptors (cross-comparison of DR4 expression to DR5,
DcR1, and DcR2 is shown in supplemental Fig. 1C, cross-
comparison of all receptor pairs has been carried out with
similar results). We used, when it was possible, experimental
binding values for WT TRAIL and the DR5-specific mutant (25,
28) or reasonable estimates (as detailed above). The model
was chosen to simulate the binding of the ligand (WT TRAIL or
D269H/E195R) to the receptors in a stepwise process and to
allow for the formation of both homotrimeric (e.g. TRAIL-
3DR5) and heterotrimeric receptor complexes (e.g. TRAIL-
2DR5-DcR2). Key assumptions of the model were as follows:
1) Preligand assembly of receptors result in homo- and het-
erodimeric receptor complexes (44, 45). 2) Formation of the
active homotrimeric receptor complex after TRAIL binding
stabilizes the complex (only for DR5 and DR4 receptors; DcR1
and DcR2 have no cytoplasmic domain or a truncated cyto-
plasmic domain, respectively, that can oligomerize; see “Ma-
terials and Methods”), and heterotrimeric receptor-TRAIL
complexes could exchange receptor subunits, as has been
shown for other members of the receptor family, TNF-R1 and
TNF-R2 (46). 3) Heterotrimeric receptor-TRAIL complexes do
not induce apoptosis (20, 24, 47). Two different scenarios
were explored: (a) no explicit cooperativity/avidity effects are
present between receptor monomers upon stepwise binding
of TRAIL, i.e. koff
A  koff
B  koff
C (supplemental Table II), and
(b) cooperative/avidity effects present between receptors of
the same species, e.g. because of interactions between the
FIG. 1. Schematic of stepwise li-
gand-induced TRAIL receptor oligo-
merization used to model the kinetics
of in vivo TRAIL receptor activation.
Receptor ligation by TRAIL was modeled
by describing all possible binding
events. Both the formation of homotri-
meric (e.g. TRAIL-3DR5) and heterotri-
meric ligand receptor complexes (e.g.
TRAIL-2DR5-DcR2) were allowed, and
binding was simulated in a stepwise
fashion. A, stepwise model of ligand-in-
duced TRAIL receptor trimerization. The
receptors could either be the death-in-
ducing (DR4 and DR5) or decoy recep-
tors (DcR1 and DcR2) indicated by the
dashed outline of the death domain. B,
active and inactive receptor complexes.
In the case of homotrimeric TRAIL-3DR5
and TRAIL-3DR4 complexes (left hand
unit), an extra step to an “activated” re-
ceptor complex was introduced to math-
ematically describe the assembly of the
intracellular death-inducing signaling
complex (consisting of the death recep-
tors, FADD and caspase-8).
Specificity of Promiscuous Ligands Regulates Signaling Kinetics
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membrane-proximal parts of the receptors or their intracellu-






and Methods”; supplemental Table 2). Of note, this latter
situation does not refer to the PLAD-PLAD interactions that
are present between the receptors in the unbound state be-
cause no such interactions have been observed in crystal
structures of TRAIL in complex with DR5 (48, 49). Unless
otherwise specified, all results refer to the first scenario: no
explicit avidity/cooperativity effects are present. A model that
did not include heteromeric interactions and only allowed the
formation of homomeric TRAIL receptor complexes was con-
structed as an additional control.
When the binding of WT TRAIL to the four TRAIL receptors
was simulated, the 1⁄2Tmax (i.e. time when 50% of the final
response was reached) of the WT TRAIL-3DR5 complex was
reached within 1100 s, whereas the 1⁄2Tmax for DR4 was
reached after 2300 s (Fig. 2A). The number of WT TRAIL-
3DR5 complexes formed after 1 h was the highest, whereas
the numbers of TRAIL-3DR4, TRAIL-3DcR1, and TRAIL-
3DcR2 were 90, 35, and 1% of the number of TRAIL-3DR5
complexes, respectively. In contrast, the 1⁄2Tmax for D269H/
E195R-3DR5 complex formation was reached after 130 s, and
the amounts of D269H/E195R-3DR4, -3DcR1, or -3DcR2
complexes were much lower even after more than 1 h of
simulation (45, 1, and 5%, respectively) (Fig. 2B). The total
number of D269H/E195R-3DR5 complexes was15% higher
than of WT TRAIL-3DR5 by the end of the simulation.
The slightly higher affinity and the 3–5-fold higher receptor
activation kinetics of D269H/E195R toward DR5 (28, 50) can-
not explain the predicted, 10-fold increase in receptor activa-
tion because a theoretical TRAIL (Control-1) variant only
showed a modest improvement in TRAIL-3DR5 activation rate
(Fig. 2, C and D). This variant has the rate constants of
D269H/E195R for DR5, but rate constants for the other re-
ceptor are the ones of WT TRAIL, and it mimics a situation of
an affinity increase for DR5 but without a concurrent large
change in receptor specificity. On the other hand, when the
ligand (theoretical TRAIL variant Control-2) was attributed, the
rate constants of WT TRAIL for DR5 and the rate constants of
D269H/E195R for the other receptors, thus mimicking recep-
tor specificity without increasing absolute affinity for DR5,
resulted in a significant enhancement in the rate of DR5 acti-
vation (Fig. 2, C and D). A third control (Control-3) mimics a
situation where the affinity increase is equivalent for all recep-
tors (modeled by increasing all WT kon rates 5-fold) and shows
only a very modest improvement in TRAIL-3DR5 activation
rate (Fig. 2, C and D).
Thus, the rate of receptor activation can be enhanced by
simply increasing the specificity toward a target receptor
without changing the binding kinetics toward this target re-
ceptor. Performing all simulations under condition 2 (by in-
cluding a cooperativity effect) revealed the same trends
(supplemental Fig. 3). In contrast, kinetics of receptor activa-
tion by WT TRAIL would be substantially faster when only
homo-oligomerization of receptors would occur. The mathe-
FIG. 2. Mathematical modeling of TRAIL receptor complex formation triggered by WT TRAIL and D269H/E195R over time. A and B,
formation of ligand-bound, homotrimeric DR4, DR5, DcR1, and DcR2 complexes after exposure to WT TRAIL (WT) (A) or D269H/E195R (DE)
(B). C and D, homotrimeric DR4 (C) and DR5 (D) formation by theoretical TRAIL variants 1, 2, and 3 (Control-1, Control-2, and Control-3).
Control-1 variant binds to DR5 with the affinity of D269H/E195R and with the affinity of WT TRAIL to the other three TRAIL receptors. Control-2
binds to DR5 with the same affinity as WT TRAIL but has the same affinity as D269H/E195R toward DR4, DcR1 and DcR2. Control-3 variant
binds to DR5 with 5-fold higher affinity (similar to D269H/E195R) and shows a concurrent equivalent change in affinity toward DR4, DcR1, and
DcR2.
Specificity of Promiscuous Ligands Regulates Signaling Kinetics
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matical model that allows only homo-oligomerization reac-
tions showed that the 1⁄2Tmax of WT TRAIL and of D269H/
E195R was already reached after 670 and 140 s, respectively
(supplemental Fig. 4). Thus, under these conditions the rate of
DR5 receptor activation by D269H/E195R is not affected,
whereas the activation rate by WT TRAIL is substantially en-
hanced, and the difference between the two ligands can then
solely be explained by the difference in kon for the DR5 re-
ceptor. Hence, according to the heteromeric interaction
model, it is therefore the decreased affinity for DR4, DcR1,
and DcR2 (i.e. its increased specificity toward DR5), in addi-
tion to the increase in association on rate for DR5 of the
mutant that changes the rate of receptor activation (Fig 2, C
and D).
To analyze the sensitivity of the model to changes in pa-
rameters, the simulations were repeated by varying WT/
D269H/E195R concentrations or the number of decoy recep-
tors per cell or by using different combinations of kon/koff rate
constants while keeping the Kd constant (using the relation-
ship Kd  koff/kon). This analysis shows that the rate of recep-
tor activation remains dependent on receptor specificity
(supplemental Fig. 5). Analyzing the 1⁄2Tmax of TRAIL-3DR5
complex formation reveals that the activation rate of DR5 by
WT TRAIL is more buffered against changes in concentration
than D269H/E195R (supplemental Fig. 6A). In contrast, the
activation of DR5 by WT TRAIL is much more sensitive to
changes in the number of decoy receptors than D269H/
E195R (supplemental Fig. 6B). The response to changes in
kon/koff combinations remains similar for WT TRAIL and
D269H/E195R (supplemental Fig. 6C). In this latter case, the
relative specificity remains the same under varying kon/koff
combinations, thereby explaining a similar behavior for WT
and D269H/E195R. In contrast, upon changing the number of
decoy receptors, the promiscuous behavior of WT TRAIL is
much more affected (either augmented or attenuated upon an
increase or decrease in the number of decoy receptors, re-
spectively) than D269H/E195R, resulting in a more sensitive
behavior of WT TRAIL. The reverse is the case upon changing
the ligand concentration, whereas the response to an increase
in WT TRAIL concentration is attenuated because of interac-
tions with all four receptors; a similar increase in D269H/
E195R concentration is more exclusively available to bind the
DR5 receptor, resulting in a more sensitive behavior of
D269H/E195R upon changes in ligand concentration.
In summary, the change in receptor activation kinetics can
be explained by the fact that WT TRAIL triggered the forma-
tion of a much higher degree of heterotrimeric receptor com-
plexes than D269H/E195R, especially during the first 30 min
of incubation (supplemental Fig. 7). This receptor pool dynam-
ically changed and gradually disappeared over the course of
incubation, because of rearrangement into active homotri-
meric complexes, resulting in a slower activation of caspase-8
and apoptotic signaling.
DR5-selective Variants Activate DR5 at a Faster Rate than
WT TRAIL—To validate the predictions of the model, Colo205
colon carcinoma cells were incubated with WT TRAIL or
D269H/E195R for varying times (5–180 min), after which the
ligands were washed out, and the incubation continued in
normal growth medium for 180 min in total. The kinetics of
death receptor activation by the two ligands was monitored
by measuring death receptor-mediated pro-caspase-8 acti-
vation and induction of cell death. While D269H/E195R only
required 3.6 0.4 min to reach 50% of its total efficacy (which
was 87.2  3.9% annexin V positivity), WT TRAIL required
60.8  4.3 min incubation with the cells to reach the same
level (i.e. 50% of its total efficacy of 80.8  5.4% annexin
V-positive dead cells), showing that receptor activation by
D269H/E195R occurs 17 times faster than with WT TRAIL
(Fig. 3A). The faster kinetics of apoptosis induction correlates
with a faster rate of receptor activation as monitored by
activation of caspase-8; D269H/E195R induced pro-
caspase-8 processing into its active form within 5 min of
incubation, whereas 60 min was required for a comparable
level of pro-caspase-8 processing by WT TRAIL (Fig. 3B). This
increase of receptor activation by D269H/E195R and subse-
quent apoptosis induction is in good agreement with the
predictions of our model (Fig. 2, A and B). Taken together,
these data suggest that the degree of TRAIL-dependent re-
ceptor hetero-oligomerization regulates the kinetics of TRAIL-
induced apoptosis.
Decoy Receptors Slow Down the Kinetics of Death Recep-
tor Activation—Another prediction of the model suggests that
preventing binding to the decoy receptors should increase the
kinetics of receptor activation and thus induction of apoptosis
by WT TRAIL but not of the DR5-specific mutant. Simulating
WT TRAIL or D269H/E195R receptor binding without decoy
receptors present showed that DR5 activation occurs 1.5-fold
faster for WT TRAIL, whereas the activation of DR5 by D269H/
E195R was not affected (Fig. 4, A and B). To confirm this
prediction, Colo205 cells were incubated with neutralizing
antibodies to DcR1 or DcR2 for 1 h prior to treatment with the
EC50 dose of WT TRAIL (20 ng/ml) or D269H/E195R (4 ng/ml),
and induction of apoptosis was measured 3 h post-treatment
using annexin V assay (Fig. 4C). The enhancement of apopto-
sis in response to decoy receptor neutralization was calcu-
lated as fold increase compared with the level of apoptosis
induced by the ligands in the absence of the neutralizing
antibodies. Neutralization of DcR1 and DcR2 resulted in sig-
nificant 1.51  0.15 and 1.22  0.07-fold increases in WT
TRAIL-induced apoptosis, respectively. Combining the neu-
tralizing antibodies to DcR1 and DcR2 had an additive effect
(1.68  0.12-fold increase of percentage apoptosis; Fig. 4C).
On the other hand, decoy receptor neutralization did not
enhance apoptosis induction by D269H/E195R treatment, in-
dicating that the decoy receptors cannot counteract death
receptor activation by D269H/E195R, only by WT TRAIL. In-
hibition of the decoy receptors also increased the kinetics of
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death receptor activation. Pretreatment of the cells with de-
coy receptor neutralizing antibodies significantly accelerated
WT TRAIL-induced but not D269H/E195R-induced accumu-
lation of annexin V-positive cells, by 1.5  0.1-fold (Fig. 4, D
and E), as well as TRAIL-mediated pro-caspase-8 processing
(Fig. 4F).
DR5-selective TRAIL Variants Are More Effective in Tumor
Cell Killing—If the kinetics of receptor activation regulates
apoptosis signaling, D269H/E195R should have a higher
tumor cell killing efficacy than WT TRAIL at lower concen-
trations and within a shorter time frame. Treatment of the
cells with 2–30 ng/ml of the DR5-selective variant D269H/
E195R for 3 h induced a 3.3–4.2-fold higher cytotoxicity
than WT TRAIL as determined by annexin V assay (Fig. 5A).
Activation of the downstream executioner caspases
(caspase-3 and -7, determined by a DEVDase assay) also
showed that a 2.9–4.1-fold lower concentration of the DR5-
selective variant was sufficient to induce the same level of
apoptosis as WT TRAIL (Fig. 5B). The higher DEVDase
activity induced by the DR5-selective mutant after 3 h of
treatment correlated with stronger pro-caspase-8 process-
ing detected by Western blotting (Fig. 5C). These results
underline our prediction that fast death receptor activation
results in the simultaneous activation of a large number of
pro-caspase-8 molecules, which in turn ensures that the
apoptotic signal spreads throughout the cells, and the tu-
mor cell commits to death.
D269H/E195R Used in Combination with Aspirin Can In-
duce Enhanced Synergism Compared with WT TRAIL—Vari-
ous chemotherapeutics and irradiation have been reported to
sensitize tumor cells to TRAIL, which correlated with induction
of DR4 and/or DR5 (51). Many of these treatments, however,
also induce the expression of the decoy receptors that can
limit the efficacy of WT TRAIL (52). For example, aspirin (2.5–5
mM for 24 h) induced the expression of DcR1 and DcR2
alongside with DR5 on the surface of Colo205 cells (Fig. 5D).
When aspirin at a dose that induced minimal loss of viability in
Colo205 cells (2.5 mM) was combined with WT TRAIL, it
enhanced WT TRAIL-induced effector caspase activity and
loss of cell viability at every time point studied (p  0.05 at
every time point where WT TRAIL was added, determined by
paired Student’s t test; Fig. 5E and supplemental Fig. 8).
However, when WT TRAIL was replaced with D269H/E195R in
the treatment, the potentiating effect, reflected in the level of
effector caspase activation, was much more pronounced,
with a significantly higher DEVDase activity in the D269H/
FIG. 3. D269H/E195R activates death-inducing TRAIL receptors and apoptosis an order of magnitude faster than WT TRAIL. Colo205
cells were treated with 30 ng/ml of WT TRAIL or D269H/E195R for the times indicated, after which the ligands were washed out, and the cells
were incubated in normal growth medium for 180 min (for TRAIL receptor activation) or for 240 min (for phosphatidylserine externalization) in
total. A, kinetics of apoptosis induction by WT TRAIL and D269H/E195R measured by annexin V assay. Apoptosis induction was expressed
relative to the percentage of death induced after 240 min without washing out the ligands  S.E. from three independent experiments. The
percentage of annexin V-positive cells induced by D269H/E195R was significantly higher at every time point than that of induced by WT TRAIL
(paired Student’s t test, p  0.05). The data were fitted with an interpolating spline using the software MatlabR from which the time to induce
50% efficacy was determined. B, kinetics of death-inducing TRAIL receptor activation by WT TRAIL and D269H/E195R was measured by
monitoring pro-caspase-8 processing with Western blotting. The levels of actin are presented as loading controls. The images are represen-
tatives of three independent experiments.
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FIG. 4. Decoy receptors reduce TRAIL-induced apoptosis and kinetics of DR4/DR5 activation. A and B, mathematical modeling of DR5
and DR4 receptor activation in the presence () or absence () of decoy receptors by WT TRAIL (A) or D269H/E195R (B). C, experimental
validation. DcR1 and DcR2 neutralization augments WT TRAIL-induced but not D269H/E195R-induced apoptosis. Colo205 cells were
incubated for 1 h with 2 g/ml of neutralizing antibodies to DcR1 and DcR2, followed by treatment with WT TRAIL (20 ng/ml) and D269H/E195R
(4 ng/ml) for 3 h. The graph shows fold increase in annexin V binding calculated by dividing the percentage apoptosis induced by the ligands
in the presence of neutralizing decoy receptor antibodies with the percentage of apoptosis induced by the ligands in the absence of the
antibodies  S.E. * indicates significant differences determined by paired t test (p  0.01) based on results from three independent
experiments. D and E, effect of decoy receptor neutralization on the kinetics of receptor activation by WT TRAIL (D) and D269H/E195R (E).
Colo205 cells were treated as described at point C. At the indicated time points, the ligands were washed out, and the cells were incubated
in normal growth medium for 240 min in total. Apoptosis induction was measured by quantifying phosphatidyl serine exposure and expressed
relative to the percentage of death induced after 240 min without washing the ligands out. The graphs show the averaged result from three
independent experiments  S.E. The percentage of annexin V-positive cells induced in the presence of DcR1/2 neutralizing antibodies was
significantly higher at every time point than that of induced by WT TRAIL alone (paired Student’s t test, p  0.05). F, neutralization of the decoy
receptors enhances TRAIL-mediated pro-caspase-8 processing. Colo205 cells were treated with WT TRAIL  DcR1/2 neutralizing antibodies
as described above in points C and D for the analysis of pro-caspase-8 processing by Western blotting. The figure shows pro-caspase-8
processing induced by WT TRAIL alone or after inhibition of the decoy receptors in alternating lanes. The image is a representative of samples
pooled together from two independent experiments. The level of actin is shown for loading control.
Specificity of Promiscuous Ligands Regulates Signaling Kinetics
10.1074/mcp.M111.013730–8 Molecular & Cellular Proteomics 11.3












E195R  aspirin samples than in the WT TRAIL  aspirin
samples after 2- and 3-h treatments (p  0.05; Fig. 5E).
Because disintegrating dead cells lose their cellular content
including caspases, the accumulative effect of the combina-
tion treatment was monitored using a viability (MTT) assay
(supplemental Fig. 8). These results show that induction of cell
death was not only faster by D269H/E195R as seen in the
DEVDase assays but also reached a higher maximum level.
The combination index was calculated for the two treatment
combinations (aspirin with WT TRAIL versus aspirin with
D269H/E195R) using the Chou-Talalay method (53), and it
clearly showed that the potentiating effect with D269H/E195R
was much larger than with WT TRAIL and across a wider
effect level range (Fa values: reduction in viability on a scale of
0.01–0.99 with 1 being the untreated control; supple-
mental Fig. 8). This confirms that enforcing fast, homotrimeric
DR5 complex formation using a receptor-selective ligand that
bypasses the formation of inhibitory TRAIL-heteromeric re-
ceptor complexes is central to effective apoptosis induction
and thus tumor cell killing.
FIG. 5. DR5-selective variants are more efficient in killing DR5-sensitive tumor cells than WT TRAIL. Colo205 cells were treated with
WT TRAIL or DR5 variant (5–30 ng/ml), and induction of apoptosis was monitored. A, phosphatidylserine externalization. The graph shows
averaged percentage apoptosis induced S.E. B, caspase activity (DEVDase), measured in a kinetic assay. Enzyme activity expressed in nmol
AMC released per min by 1 mg of total cellular protein. C, Western blot analysis of pro-caspase-8 cleavage (activation) induced by WT TRAIL
or D269H/E195R. D269H/E195R used in combination with aspirin can induce enhanced synergism compared with WT TRAIL. D, aspirin
induces expression of DR5, DcR1, and DcR2 on the cell surface. Colo205 cells were treated with 5 mM aspirin for 24 h, and cell surface
expression of DR4, DR5, DcR1, and DcR2 was measured by immunostaining and detected with flow cytometry. The histograms shown include
isotype (negative) control (black, open peak), untreated Colo205 (labeled Cont; gray, closed peak) and aspirin-treated Colo205 (labeled
Asp; gray, open peak) samples. The histograms are representatives of three independent experiments. E, caspase activation by combined
treatment with aspirin plus WT TRAIL or D269H/E195R. The cells were treated with 5 mM aspirin for 24 h followed by 5 ng/ml of WT TRAIL
or D269H/E195R for the times indicated, after which the cells were harvested, and DEVDase activity as a measure of cell death was
measured in cell lysates. DEVDase activity was expressed as average nmol of AMC released per min by 1 mg of total cellular protein. The
results are the mean values  S.D. of three independent experiments. * and ** indicate significant differences between the connected
sample pairs (p  0.05).
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The outcome of signaling events of ligand receptor systems
that consist of multiple receptors and/or ligands is complex;
such multicomponent systems can yield different biological
responses and the individual components can add different
layers of regulation. Because these systems enable diverse
biological responses, they are very common. Examples in-
clude the vascular endothelial growth factor ligand receptor
system, the fibroblast growth factor, or the TRAIL ligand re-
ceptor systems (2, 4, 8).
Extrapolation of kinetic and equilibrium constants from in
vitro measurements of purified recombinant ligands and re-
ceptors to in vivo conditions is challenging when dealing with
such complex cases as the molecule that triggers the signal
can be trapped in nonproductive interactions that equilibrate
slowly with the productive complex. This is not only the case
with the aforementioned multiple receptor/ligand systems but
in principle also extends to promiscuous intracellular adaptor
proteins that can be trapped in nonproductive interactions.
Not accounting for these nonproductive interactions in signal
transduction simulations can result in overestimating of (acti-
vation) kinetics and, subsequently, result in the wrong inter-
pretation of the underlying signaling networks and the biolog-
ical response.
We hypothesized that the kinetics of receptor activation is a
major determinant in signal transduction and that formation of
nonproductive interactions can severely change the observed
activation kinetics and even the final biological response. As a
model, we choose one such multicomponent system, TRAIL
and its cognate receptors, and examined how apoptosis sig-
naling by the different TRAIL receptors is regulated. Tight
regulation of apoptosis signaling is crucial for the survival of
multicellular organisms and deregulation of apoptosis culmi-
nates in various diseases (e.g. cancers, neurodegenerative
diseases, and autoimmune diseases) (54). Regulation of apo-
ptosis is provided at several levels in the apoptosis signaling
cascade (both upstream, at the level of the receptor and at
various downstream levels). With the aid of a previously de-
veloped DR5-selective TRAIL variant and mathematical mod-
eling, we investigated the regulation provided by the presence
of multiple TRAIL binding receptors and their competition for
the ligand.
Wild type TRAIL can bind to its death receptors and decoy
receptors with a broadly similar degree of affinity (26, 49). The
DR5-selective TRAIL variant has a 3–5-fold increase in DR5
binding kinetics combined with a many fold decrease in bind-
ing kinetics to DR4 and DcR1 and a modest decrease in
binding kinetics to DcR2 (28, 50). At first sight, common sense
would likely predict a 3–5-fold increase in the kinetics of
apoptosis induction for this DR5 selective variant. However,
our studies, qualitatively in line with the predictions of our
simulation model, revealed that the DR5-selective TRAIL var-
iant both activates the death-inducing DR5 receptor and in-
duces apoptosis at 20 times faster than WT TRAIL. In a
previous study, we demonstrated the same, i.e. faster recep-
tor-activation kinetics, using a DR4-selective TRAIL variant
(7).
The simulation model we have generated showed that the
higher the specificity of the ligand toward the target receptor,
the faster it will activate that receptor. Furthermore, initiation
of the signal transduction pathway is regulated kinetically by
the nonsignaling TRAIL receptor complexes (e.g. TRAIL-
2DR5-DcR2 or TRAIL-DR5–2DcR2). A low degree of receptor
specificity of the ligand leads to the transient formation of
heteromeric receptor complexes that gradually rearrange into
functional, homotrimeric complexes. In case of WT TRAIL, we
have found that it results in a slow activation of the death-
inducing receptors and cleavage of pro-caspase-8. This not
only slows down the initiation of the signal but can completely
abrogate it. Cleaved caspase-8, especially the catalytically
active p18 fragment, has been shown to have a short half-life
time of 20 min because it is targeted for proteasomal deg-
radation by caspase-8- and -10-associated RING proteins 1
and 2 (CARP-1 and -2) (15, 17). Slow and inefficient pro-
caspase-8 activation is thus insufficient to induce apoptosis,
and this is one of the reasons tumors can be sensitized
toward TRAIL by proteasome inhibitors (15, 57, 58). A ligand
with high specificity toward one receptor can avoid this kinetic
hindrance driven by nonsignaling heteromeric complexes and
trigger much faster receptor activation, thereby producing
high amounts of activated caspase-8 molecules in a short
time, resulting in fast and robust induction of apoptosis. Using
the DR5 selective TRAIL variant or WT TRAIL ligand in the
presence of neutralizing antibodies against the nonsignaling
TRAIL receptors, we have provided evidence that this hypoth-
esis is true.
Tight regulation of apoptosis signaling is crucial for the
survival of multicellular organisms and loss of this regulation
contributes to serious diseases (e.g. cancers, autoimmune
diseases, neurodegenerative disorders) (54). For example,
spurious or low level caspase activation that is insufficient
to trigger a unified apoptotic response of the cell but could
potentially cause local damage by inducing intermediate
states of partial cell death is actively removed by proteolysis
(16). In line with our results, analysis of the kinetics of
apoptosis at a single cell level showed that effector caspase
activation is an all or nothing event and is independent of
the dosage of the apoptosis-inducing stimulus (59). On the
other hand, pro-caspase-8 activation was found to occur in
a dose-dependent manner in response to TRAIL (60). These
results insinuate that the commitment to apoptosis is most
likely occur at the level immediately downstream of the
receptor (14, 61). Until caspase-8 activity reaches a certain
threshold, the death signal is not transmitted to the execu-
tion machinery and thus guarantees the uniform “all-or-
nothing” response of the cell upon commitment to death
(14, 61).
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It is well established that overexpression of the decoy re-
ceptors inhibits TRAIL-induced apoptosis (19, 52). However,
the potency of the decoy receptors expressed at endogenous
levels to antagonize TRAIL-induced apoptosis and thus their
real physiological function is largely unknown. Previous stud-
ies also found that in some tumor cells, the expression of the
decoy receptors did not correlate with TRAIL sensitivity (62–
64). This could be due to inhibitors of apoptosis acting down-
stream of the receptor (e.g. c-FLIP, Bcl-2, XIAP) or compart-
mentalization of the receptors (31, 55), but the exact
mechanism of decoy receptor-mediated TRAIL antagonism is
not fully understood yet. Apart from sequestering available
TRAIL (25), DcR1 and DcR2 can also interfere with the forma-
tion of functional, homotrimeric DR4 and DR5 signaling com-
plexes. Clancy et al. (24) reported that DcR2 can bind to DR5
in a ligand (TRAIL)-independent manner via PLAD-PLAD do-
main interactions of the receptors, which inhibits the forma-
tion of functional TRAIL-DR5 signaling complexes. On the
other hand, a study by Me´rino et al. (20) showed that TRAIL
can co-recruit DcR2 with DR5, producing a heteromeric, in-
active receptor complex, thus equally inhibiting DR5 function
but in a ligand-dependent manner. Our results suggest that
rather than simply sequestering available TRAIL, decoy recep-
tors might provide a kinetically driven buffer against unwar-
ranted or spurious caspase 8 activation by low concentrations
of TRAIL by forming inactive heteromeric receptor complexes
in a ligand-dependent way and thereby reduce noise in
TRAIL-induced apoptosis signaling.
In conclusion, we can state that receptors of a multirecep-
tor system can work in concert to create temporal control of
signal transduction. Our results indicate that signal transduc-
tion induced by promiscuous ligands is largely determined by
nonproductive interactions and consequently, by the relative
amount of the different receptors sharing the same ligand.
The observation that binding of a ligand to multiple types of
receptor can slow down the activation of the preferred target
receptor also has implications at a more applied level. It can
be used to increase the efficacy of promiscuous cytokines to
a particular receptor with the aim of developing more potent
therapeutics. Faster kinetics can be achieved by increasing
the kon for the target receptor and by simultaneously decreas-
ing the affinity for the other receptors, i.e. both the relative and
the absolute affinity for the target receptor must increase to
generate fast acting and thus strong agonists/antagonists.
For example, in case of WT TRAIL, considering its short in vivo
half-life time (56), faster receptor binding kinetics (and faster
induction of apoptosis) can generate a considerable thera-
peutic advantage.
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